Virios Therapeutics, Inc. (VIRI) News
Filter VIRI News Items
VIRI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VIRI News From Around the Web
Below are the latest news stories about VIRIOS THERAPEUTICS INC that investors may wish to consider to help them evaluate VIRI as an investment opportunity.
Virios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call TranscriptVirios Therapeutics, Inc. (NASDAQ:VIRI) Q3 2023 Earnings Call Transcript November 13, 2023 Virios Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.1. Operator: Good day, and welcome to the Virios Therapeutics, Inc. Third Quarter 2023 Earnings Update. At this time, all participants have been placed on a listen-only mode. Please be advised […] |
VIRI: Provides Overview of Phase 3 Program in FibromyalgiaBy David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Overview of Phase 3 Program for IMC-1 in Fibromyalgia Virios Therapeutics, Inc. (NASDAQ:VIRI) is developing IMC-1 (combination of famciclovir and celecoxib) as a therapy for fibromyalgia (FM). The company previously reported results from the Phase 2b FORTRESS trial in September 2022. Topline results showed that the |
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the third quarter ended September 30, 2023. Key Highlights and Upcoming Milestones Having secured FDA guidance on our plan to progress IM |
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023ATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID, announced today that it will report third quarter 2023 financial results on Monday, November 13, 2023 before the open of the financial markets. Management will also host a webcast and conference call on November |
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY. The live and archived webcast of the session may b |
Virios Therapeutics Announces Termination of At-The-Market Sales AgreementATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID, today announced that it provided notice of termination of the Capital on Demand™ Sales Agreement entered into between the Company and JonesTrading Institutional Services LLC on July 14, 2023 (the “Sales Agreement”). The Company has i |
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023ATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID (“LC”), announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the SHARE™️ Series Monday Management Update for investors on Monday, September 18, 2023, at 11:00 am ET. This virtual event combine |
VIRI: Phase 3 Program in Fibromyalgia to Initiate in mid-2024…By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Update on Phase 3 Program for IMC-1 in Fibromyalgia Virios Therapeutics, Inc. (NASDAQ:VIRI) is developing IMC-1 (combination of famciclovir and celecoxib) as a therapy for fibromyalgia (FM). The company previously reported results from the Phase 2b FORTRESS trial in September 2022. Topline results showed that the |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting the week off right with a breakdown of the biggest pre-market stock movers worth knowing about on Monday morning! |
Virios Therapeutics Announces Halt to At-The-Market Offering SalesATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (“FM”) and Long-COVID, today announced that it has advised its sales agent, JonesTrading Institutional Services LLC (“JonesTrading”), to cease sales under the Capital on Demandtm Sales Agreement entered into between the Company and JonesTrading on Ju |